Effect of leucovorin (folinic acid) on the developmental quotient of children with Down's syndrome (trisomy 21) and influence of thyroid status

Henri Blehaut, Clotilde Mircher, Aimé Ravel, Martine Conte, Veronique de Portzamparc, Gwendael Poret, Françoise Huon de Kermadec, Marie-Odile Rethore, Franck G Sturtz, Henri Blehaut, Clotilde Mircher, Aimé Ravel, Martine Conte, Veronique de Portzamparc, Gwendael Poret, Françoise Huon de Kermadec, Marie-Odile Rethore, Franck G Sturtz

Abstract

Background: Seven genes involved in folate metabolism are located on chromosome 21. Previous studies have shown that folate deficiency may contribute to mental retardation in Down's syndrome (DS).

Methodology: We investigated the effect of oral folate supplementation (daily dose of 1.0+/-0.3 mg/kg) on cognitive functions in DS children, aged from 3 to 30 months. They received 1 mg/kg leucovorin or placebo daily, for 12 months, in a single-centre, randomised, double-blind study. Folinic acid (leucovorin, LV) was preferred to folic acid as its bioavailability is higher. The developmental age (DA) of the patients was assessed on the Brunet-Lezine scale, from baseline to the end of treatment.

Results: The intent-to-treat analysis (113 patients) did not show a positive effect of leucovorin treatment. However, it identified important factors influencing treatment effect, such as age, sex, and concomitant treatments, including thyroid treatment in particular. A per protocol analysis was carried out on patients evaluated by the same examiner at the beginning and end of the treatment period. This analysis of 87 patients (43 LV-treated vs. 44 patients on placebo) revealed a positive effect of leucovorin on developmental age (DA). DA was 53.1% the normal value with leucovorin and only 44.1% with placebo (p<0.05). This positive effect of leucovorin was particularly strong in patients receiving concomitant thyroxin treatment (59.5% vs. 41.8%, p<0.05). No adverse event related to leucovorin was observed.

Conclusion: These results suggest that leucovorin improves the psychomotor development of children with Down's syndrome, at least in some subgroups of the DS population, particularly those on thyroxin treatment.

Trial registration: ClinicalTrials.gov, NCT00294593.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Folate metabolic pathways and methylation…
Figure 1. Folate metabolic pathways and methylation cycle.
Gene names are shown in italics and according to the HGNC approved names. Genes in boxes are located on chromosome 21. Abbreviations used are: DHF: dihrofolate; THF: tetrahydrofolate; 5,10-CH2 THF: N5,N10-methylene THF; 5,10-CH THF: N5,N10-methenyl THF; 5-CH3 THF: N5-methyl THF; GAR: glycinamide ribonucleotide; FGAR: formyl-GAR; GSH: reduced form of glutathione; GSSG: oxidised form of glutathione; ROS: reactive oxygen species.
Figure 2. Flow chart of participants in…
Figure 2. Flow chart of participants in the clinical trial.
N = number of patients. Not eligible: patients with no efficacy and safety data after V1. Early premature V1 discontinuation: patients with no efficacy and safety data after V1. Late premature V2 discontinuation: patients not evaluated after V2 (6 months). Per protocol analysis: patients assessed by the same psychometric examiner during at least 2 visits. Major protocol violation: patients not assessed by the same psychometric examiner at 2 consecutive visits. Completed: patients without protocol violation and with 12 months of efficacy and safety data.
Figure 3. Effect of leucovorin treatment on…
Figure 3. Effect of leucovorin treatment on change in global developmental age (DA).
DA was measured for the patients receiving placebo or LV, in the per protocol population (87 patients) and as a function of a thyroxin treatment (N = number of patients, % change in developmental age with respect to a non-DS age-matched population).

References

    1. Lejeune J, Gautier M, Turpin R. Study of somatic chromosomes from 9 mongoloid children. C R Hebd Seances Acad Sci. 1959;248:1721–1722.
    1. Epstein CJ. Down syndrome (Trisomy 21). In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 7th ed. New York: McGraw-Hill, Health Professions Division; 1995. pp. 749–794.
    1. Antonarakis SE, Lyle R, Dermitzakis ET, Reymond A, Deutsch S. Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat Rev Genet. 2004;5:725–738.
    1. Dauphinot L, Lyle R, Rivals I, Dang MT, Moldrich RX, et al. The cerebellar transcriptome during postnatal development of the Ts1Cje mouse, a segmental trisomy model for Down syndrome. Hum Mol Genet. 2005;14:373–384.
    1. Chapman RS, Hesketh LJ. Behavioral phenotype of individuals with Down syndrome. Ment Retard Dev Disabil Res Rev. 2000;6:84–95.
    1. Chapman RS, Hesketh LJ. Language, cognition, and short-term memory in individuals with Down syndrome. Downs Syndr Res Pract. 2001;7:1–7.
    1. Pogribna M, Melnyk S, Pogribny I, Chango A, Yi P, et al. Homocysteine metabolism in children with Down syndrome: in vitro modulation. Am J Hum Genet. 2001;69:88–95.
    1. Botez MI, Botez T, Leveille J, Bielmann P, Cadotte M. Neuropsychological correlates of folic acid deficiency: facts and hypotheses. In: Botez MI, Reynolds EH, editors. Folic acid in neurology, psychiatry end internal medicine. New York: Raven Press; 1979. pp. 435–461.
    1. Enk C, Hougaard K, Hippe E. Reversible dementia and neuropathy associated with folate deficiency 16 years after partial gastrectomy. Scand J Haematol. 1980;25:63–66.
    1. Quadri P, Fragiacomo C, Pezzati R, Zanda E, Forloni G, et al. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr. 2004;80:114–122.
    1. Quadri P, Fragiacomo C, Pezzati R, Zanda E, Tettamanti M, et al. Homocysteine and B vitamins in mild cognitive impairment and dementia. Clin Chem Lab Med. 2005;43:1096–1100.
    1. Blaise SA, Nedelec E, Schroeder H, Alberto JM, Bossenmeyer-Pourie C, et al. Gestational vitamin B deficiency leads to homocysteine-associated brain apoptosis and alters neurobehavioral development in rats. Am J Pathol. 2007;170:667–679.
    1. Durga J, van Boxtel MP, Schouten EG, Bots ML, Kok FJ, et al. Folate and the methylenetetrahydrofolate reductase 677C–>T mutation correlate with cognitive performance. Neurobiol Aging. 2006;27:334–343.
    1. Ramos MI, Allen LH, Haan MN, Green R, Miller JW. Plasma folate concentrations are associated with depressive symptoms in elderly Latina women despite folic acid fortification. Am J Clin Nutr. 2004;80:1024–1028.
    1. Ramos MI, Allen LH, Mungas DM, Jagust WJ, Haan MN, et al. Low folate status is associated with impaired cognitive function and dementia in the Sacramento Area Latino Study on Aging. Am J Clin Nutr. 2005;82:1346–1352.
    1. Malouf M, Grimley EJ, Areosa SA. Folic acid with or without vitamin B12 for cognition and dementia. Cochrane Database Syst Rev. 2003:CD004514.
    1. Botez MI, Cadotte M, Beaulieu R, Pichette LP, Pison C. Neurologic disorders responsive to folic acid therapy. Can Med Assoc J. 1976;115:217–223.
    1. Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet. 2007;369:208–216.
    1. Yang-Feng TL, Ma YY, Liang R, Prasad PD, Leibach FH, et al. Assignment of the human folate transporter gene to chromosome 21q22.3 by somatic cell hybrid analysis and in situ hybridization. Biochem Biophys Res Commun. 1995;210:874–879.
    1. Roizen NJ, Patterson D. Down's syndrome. Lancet. 2003;361:1281–1289.
    1. Lejeune J, Rethore MO, de Blois MC, Peeters M, Naffah J, et al. Amino acids and trisomy 21. Ann Genet. 1992;35:8–13.
    1. Gueant JL, Anello G, Bosco P, Gueant-Rodriguez RM, Romano A, et al. Homocysteine and related genetic polymorphisms in Down's syndrome IQ. J Neurol Neurosurg Psychiatry. 2005;76:706–709.
    1. Chadefaux B, Ceballos I, Hamet M, Coude M, Poissonnier M, et al. Is absence of atheroma in Down syndrome due to decreased homocysteine levels? Lancet. 1988;2:741.
    1. David O, Fiorucci GC, Tosi MT, Altare F, Valori A, et al. Hematological studies in children with Down syndrome. Pediatr Hematol Oncol. 1996;13:271–275.
    1. Peeters MA, Poon A, Zipursky A, Lejeune J. Toxicity of leukaemia therapy in children with Down syndrome. Lancet. 1986;2:1279.
    1. Taub JW, Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer. 2005;44:33–39.
    1. Peeters MA, Rethore MO, Lejeune J. In vivo folic acid supplementation partially corrects in vitro methotrexate toxicity in patients with Down syndrome. Br J Haematol. 1995;89:678–680.
    1. Lejeune J, Peeters M, Rethore MO, de Blois MC. Homocysteine and the methotrexate toxicity in trisomy 21. Cancer Chemother Pharmacol. 1991;27:331–332.
    1. Lejeune J, Rethore MO, de Blois MC, Peeters M. Infantile psychosis, pseudo-Alzheimer syndrome, and trisomy 21. A trial of treatment with folinic acid: preliminary report. Therapie. 1989;44:115–121.
    1. Lejeune J. Pathogenesis of mental deficiency in trisomy 21. Am J Med Genet. 1990;7(Suppl):20–30.
    1. Bennett FC, McClelland S, Kriegsmann EA, Andrus LB, Sells CJ. Vitamin and mineral supplementation in Down's syndrome. Pediatrics. 1983;72:707–713.
    1. Bidder RT, Gray P, Newcombe RG, Evans BK, Hughes M. The effects of multivitamins and minerals on children with Down syndrome. Dev Med Child Neurol. 1989;31:532–537.
    1. Smith GF, Spiker D, Peterson CP, Cicchetti D, Justine P. Use of megadoses of vitamins with minerals in Down syndrome. J Pediatr. 1984;105:228–234.
    1. Spector R. Cerebrospinal fluid folate and the blood-brain barrier. In: Botez MI, Reynolds EH, editors. Folic acid in neurology, psychiatry, and internal medicine. New York: Raven Press; 1979. pp. 187–194.
    1. Prasher VP. Down syndrome and thyroid disorders: a review. Downs Syndr Res Pract. 1999;6:25–42.
    1. Fort P, Lifshitz F, Bellisario R, Davis J, Lanes R, et al. Abnormalities of thyroid function in infants with Down syndrome. J Pediatr. 1984;104:545–549.
    1. Josse D. Issy-Les-Moulineaux (France): Etablissements d'Applications Psychotechniques; 1997. Brunet-Lezine revise, echelle de developpement psychomoteur de la premiere enfance.308
    1. Lezine I, Brunet O. Presentation of a French scale of tests for infants. Ann Med Psychol (Paris) 1950;108:499.
    1. Francois LL, des Portes V. The main stages of psychomotor development from 0 to 3 years of age. Rev Prat. 2004;54:1991–1997.
    1. Soldin SJ, Brugnara C, Hicks JM. Washington, DC: AACC Press; 1999. Pediatric reference ranges.
    1. Coste J, Bouee S, Ecosse E, Leplege A, Pouchot J. Methodological issues in determining the dimensionality of composite health measures using principal component analysis: case illustration and suggestions for practice. Qual Life Res. 2005;14:641–654.
    1. Brocker P, Bonhomme P, Lods JC. Folates: de la deficience a la carence. La Revue de Geriatrie. 1990;15:365–373.
    1. Ellis JM, Tan HK, Gilbert RE, Muller DP, Henley W, et al. Supplementation with antioxidants and folinic acid for children with Down's syndrome: randomised controlled trial. BMJ. 2008;336:594–597.
    1. Fernandez V, Tapia G, Varela P, Romanque P, Cartier-Ugarte D, et al. Thyroid hormone-induced oxidative stress in rodents and humans: a comparative view and relation to redox regulation of gene expression. Comp Biochem Physiol C Toxicol Pharmacol. 2006;142:231–239.
    1. Venditti P, Di Meo S. Thyroid hormone-induced oxidative stress. Cell Mol Life Sci. 2006;63:414–434.
    1. Erdamar H, Demirci H, Yaman H, Erbil MK, Yakar T, et al. The effect of hypothyroidism, hyperthyroidism, and their treatment on parameters of oxidative stress and antioxidant status. Clin Chem Lab Med. 2008;46:1004–1010.
    1. Santos GM, Afonso V, Barra GB, Togashi M, Webb P, et al. Negative regulation of superoxide dismutase-1 promoter by thyroid hormone. Mol Pharmacol. 2006;70:793–800.
    1. Catargi B, Parrot-Roulaud F, Cochet C, Ducassou D, Roger P, et al. Homocysteine, hypothyroidism, and effect of thyroid hormone replacement. Thyroid. 1999;9:1163–1166.
    1. Nedrebo BG, Ericsson UB, Nygard O, Refsum H, Ueland PM, et al. Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism. 1998;47:89–93.
    1. Diekman MJ, van der Put NM, Blom HJ, Tijssen JG, Wiersinga WM. Determinants of changes in plasma homocysteine in hyperthyroidism and hypothyroidism. Clin Endocrinol (Oxf) 2001;54:197–204.
    1. Hussein WI, Green R, Jacobsen DW, Faiman C. Normalization of hyperhomocysteinemia with L-thyroxine in hypothyroidism. Ann Intern Med. 1999;131:348–351.
    1. Hustad S, Nedrebo BG, Ueland PM, Schneede J, Vollset SE, et al. Phenotypic expression of the methylenetetrahydrofolate reductase 677C–>T polymorphism and flavin cofactor availability in thyroid dysfunction. Am J Clin Nutr. 2004;80:1050–1057.
    1. Gueant JL, Xiaohong L, Ortiou S, Gerard P, Shue S, et al. The association between plasma homocysteine and holo-transcobalamin and the transcobalamin 776C–>G polymorphism is influenced by folate in the absence of supplementation and fortified diet. Am J Clin Nutr. 2006;83:171–172.
    1. Ayav A, Alberto JM, Barbe F, Brunaud L, Gerard P, et al. Defective remethylation of homocysteine is related to decreased synthesis of coenzymes B2 in thyroidectomized rats. Amino Acids. 2005;28:37–43.
    1. Chen X, Jhee KH, Kruger WD. Production of the neuromodulator H2S by cystathionine beta-synthase via the condensation of cysteine and homocysteine. J Biol Chem. 2004;279:52082–52086.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren